Rocket


News + Filings
Key Docs
Ownership


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Medicenna Therapeutics Corp. (MDNA) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/10/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Medicenna Therapeutics Appoints Humphrey Gardner, M.D., as Chief Medical Officer Dr. Gardner brings over 30 years of experience leading clinical development to support innovative oncology programs and translational research at global biopharmaceutical companies and major academic institutions TORONTO and HOUSTON, Oct. 10, 2023 -- Medicenna Therapeutics Corp. , a clinical-stage immunotherapy company focused on the development of novel Superkines, today announced the appointment of Humphrey Gardner, M.D., as Chief Medical Officer to lead the development strategy and execution of Medicenna’s clinical programs. “We are thrilled to welcome Dr. Gardner as Medicenna’s new CMO and member of our management team. Dr. Gardner holds remarkable leadership experiences advancing immune-based therapies fo..."
10/03/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Medicenna Presents Preclinical MDNA223 BiSKIT Data at the AACR Special Conference on Tumor Immunology and Immunotherapy"
09/28/2023 6-K Quarterly results
09/28/2023 6-K Quarterly results
08/14/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Medicenna Establishes Boston Presence, Appoints Brent Meadows as Chief Business Officer, and Bolsters Management"
08/09/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K"
08/08/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Medicenna Appoints Dr. Arash Yavari as Chair of Development Advisory Committee Development Advisory Committee strengthened with the expertise and leadership of Dr. Yavari"
08/04/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Medicenna Therapeutics to Provide Clinical Update from Phase 1/2 ABILITY Study on August 9, 2023"
08/01/2023 6-K Quarterly results
07/28/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Interim Financial Statements for the period ended June 30, 2023",
"Management’ s Discussion and Analysis for the period ended June 30, 2023",
"Form 52- 109F2 Certification of Interim Filings Full Certificate – CEO",
"Form 52- 109F2 Certification of Interim Filings Full Certificate – CFO",
"Medicenna Reports First Quarter Fiscal 2024 Financial Results and Operational Highlights"
07/25/2023 6-K Quarterly results
07/06/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Medicenna Extends Period to Exercise Certain Warrants TORONTO and HOUSTON, July 05, 2023 -- Medicenna Therapeutics Corp. , a clinical stage immunotherapy company, today announced that it has received conditional approval from the Toronto Stock Exchange to extend the expiry date of a total of 1,549,052 outstanding common share purchase warrants of the Company originally issued on October 17, 2019 as part of a public offering of units of the Company. Each warrant is exercisable for a common share of the Company at a price of $1.75 per Common Share and set to expire on July 17, 2023. The Company has extended the expiry date of such Warrants until October 17, 2024, with such extension being effective on July 17, 2023. All other terms of the Warrants, including the exercise price, remain unchan..."
04/27/2023 6-K Quarterly results
04/18/2023 6-K Quarterly results
04/17/2023 6-K Quarterly results
03/30/2023 6-K Quarterly results
03/15/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Investor Contact"
03/02/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Medicenna to Present at the Oppenheimer 33rd Annual Healthcare Conference"
02/07/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Interim Financial Statements for the period ended December 31, 2022",
"Management’ s Discussion and Analysis for the period ended December 31, 2022",
"Form 52- 109F2 Certification of Interim Filings Full Certificate – CEO",
"Form 52- 109F2 Certification of Interim Filings Full Certificate – CFO",
"Medicenna Reports Third Quarter Fiscal 2023 Financial Results and Operational Highlights"
01/31/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Medicenna to Present at the 2023 Guggenheim Oncology Conference"
01/26/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Medicenna to Announce Third Quarter Fiscal 2023 Financial Results and Operational Highlights on Tuesday, February 7, 2023"
01/05/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Medicenna Strengthens Intellectual Property Protection for MDNA11 and BiSKITs™ Programs with Issuance of U.S. Patent"
11/10/2022 6-K Quarterly results
11/04/2022 6-K Quarterly results
10/28/2022 6-K Quarterly results
10/25/2022 6-K Quarterly results
10/17/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"First supplemental warrant indenture between the Company and the TSX Trust Company"
10/05/2022 6-K Quarterly results
09/30/2022 6-K Quarterly results
09/28/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Investor Contact"
09/22/2022 6-K Quarterly results
09/22/2022 6-K Quarterly results
09/21/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Investor Contact"
09/13/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Medicenna Announces Clinical Collaboration with Merck to evaluate MDNA11 in combination with KEYTRUDA® in ABILITY Trial ABILITY Study will evaluate MDNA11, a highly selective long-acting IL-2 Superkine, in combination with Merck’s KEYTRUDA® for treatment of patients with advanced solid tumors TORONTO and HOUSTON, Sept. 13, 2022 -- Medicenna Therapeutics Corp. , a clinical stage immuno-oncology company, today announced that it has entered into a clinical trial collaboration and supply agreement with Merck to evaluate MDNA11, Medicenna’s “beta-only” long-acting IL-2 super-agonist in combination with KEYTRUDA , Merck’s anti-PD-1 therapy, in the ongoing Phase 1/2 ABILITY Study. The ABILITY Study is a Phase 1/2 trial designed to assess the safety, pharmacokinetics , pharmacodynamics and prelimi..."
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy